EcoDrugPlus

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSMAMG00000026676
Gene Symbol: CHRM5
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSMAMG00000002586
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSMAMG00000025277
Gene Symbol: CHRM2A
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSMAMG00000002439
Gene Symbol: CHRM5B
3 Cross references
189 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 3

Ensembl ID : ENSMAMG00000002690
Gene Symbol: CHRNA3
2 Cross references
202 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSMAMG00000013354
Gene Symbol: CHRNA7A
2 Cross references
205 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Beta 2

Ensembl ID : ENSMAMG00000013816
Gene Symbol: CHRNB2
2 Cross references
197 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSMAMG00000012076
Gene Symbol: F2R
3 Cross references
216 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSMAMG00000021961
Gene Symbol: F3
2 Cross references
199 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSMAMG00000022778
Gene Symbol: F7L
3 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSMAMG00000022771
Gene Symbol: F10
3 Cross references
240 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSMAMG00000006494
Gene Symbol: LOC113126509
2 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).